| DeFronzo, Ralph A |
NCT02911792: Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With Hyperfiltration |
|
|
| Completed | 4 | 72 | US | Dapagliflozin, Farxiga, Metformin, Metformin-XR, Glipizide 5 MG | The University of Texas Health Science Center at San Antonio, AstraZeneca | Diabetes Mellitus, Type 2 | 07/23 | 07/23 | | |
NCT01107717: Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM |
|
|
| Completed | 4 | 318 | US | metformin\pioglitazone\exenatide, metformin, glyburide and glargine | The University of Texas Health Science Center at San Antonio, American Diabetes Association, Amylin Pharmaceuticals, LLC., National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Diabetes | 02/23 | 02/23 | | |
|
NCT03953963: Evaluation of Intra-Abdominal Fat Extraction Using HydraSolve T2D™ in Obese Subjects With Type 2 Diabetes |
|
|
| Recruiting | N/A | 12 | US | HydraSolve T2D™ | Medality Medical | Diabetes Mellitus, Type 2, Insulin Resistance | 07/21 | 03/22 | | |
NCT02969798: Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT) |
|
|
| Recruiting | N/A | 700 | US | Dapagliflozin, farxiga, Saxagliptin, onglyza, Pioglitazone, actos, Metformin, glucophage | The University of Texas Health Science Center at San Antonio, American Diabetes Association, AstraZeneca, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Diabetes Mellitus, Type 2, Impaired Glucose Tolerance (IGT), Impaired Fasting Glucose (IFG) | 03/26 | 07/27 | | |
| Cersosimo, Eugenio |
NCT02981966: Effect of Dapagliflozin on Hepatic and Renal Glucose Metabolism Subjects |
|
|
| Completed | 4 | 32 | US | Dapagliflozin, Farxiga, Placebo | The University of Texas Health Science Center at San Antonio, AstraZeneca | Diabetes Mellitus, Type 2 | 04/22 | 05/23 | | |
NCT02981069: Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DM |
|
|
| Completed | 4 | 90 | US | Dapagliflozin, Farxiga, Exenatide, Byetta, Bydureon, Placebo | The University of Texas Health Science Center at San Antonio, AstraZeneca | Diabetes Mellitus, Type 2 | 07/22 | 03/23 | | |
NCT03953963: Evaluation of Intra-Abdominal Fat Extraction Using HydraSolve T2D™ in Obese Subjects With Type 2 Diabetes |
|
|
| Recruiting | N/A | 12 | US | HydraSolve T2D™ | Medality Medical | Diabetes Mellitus, Type 2, Insulin Resistance | 07/21 | 03/22 | | |
NCT02969798: Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT) |
|
|
| Recruiting | N/A | 700 | US | Dapagliflozin, farxiga, Saxagliptin, onglyza, Pioglitazone, actos, Metformin, glucophage | The University of Texas Health Science Center at San Antonio, American Diabetes Association, AstraZeneca, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Diabetes Mellitus, Type 2, Impaired Glucose Tolerance (IGT), Impaired Fasting Glucose (IFG) | 03/26 | 07/27 | | |
| Patel, Sandeep |
| Active, not recruiting | N/A | 44467 | US | | Guardant Health, Inc., Premier Research Group plc | Colorectal Cancer | 03/24 | 12/25 | | |
| Chen, Stephen |
| Recruiting | N/A | 114 | US, RoW | GPX® Embolic Device | Fluidx Medical Technology, Inc., Bright Research Partners | Embolism, Vascular Tumor, Renal Angiomyolipoma, Renal Cell Carcinoma, Bone Tumor, Portal Vein Embolism | 05/26 | 09/26 | | |
